SCHEDULE: Wellington Management Discloses 10% Stake in ProMIS Neurosciences

Wellington Management Group LLP and its affiliates have reported beneficial ownership of 10% of ProMIS Neurosciences, Inc. common stock as of March 31, 2026.

Summary

• Wellington Management Group LLP, along with its affiliates Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP, has filed a Schedule 13G.
• This filing indicates beneficial ownership of 895,871 shares of ProMIS Neurosciences, Inc. common stock.
• This ownership represents 10.0% of the outstanding common stock, based on approximately 8,967,693 shares outstanding as of March 25, 2026.
• The reported shares include 696,378 shares held directly and 199,493 shares underlying warrants held by Wellington Biomedical Innovation Master Investors (Cayman) II L.P.
• The filing notes an issuance limitation on some warrants, preventing exercise if it would result in beneficial ownership exceeding 9.99%.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral; it indicates significant institutional interest but does not provide operational or financial performance data for ProMIS Neurosciences itself.

Positives

• Significant institutional ownership by a major asset manager like Wellington Management can signal confidence in the company's long-term prospects.
• The filing confirms a substantial stake, indicating active investment and potential for continued support.

Negatives

• The ownership percentage is capped at 9.99% due to warrant issuance limitations, suggesting a deliberate strategy to avoid triggering higher disclosure thresholds or control implications.
• The filing is a Schedule 13G, which is typically for passive investors, but the specific details around warrant exercise limitations warrant further scrutiny.

Risks

• Potential for future changes in beneficial ownership, as the 10% stake is held through various entities and includes warrants.
• The issuance limitation on warrants could restrict the ability to increase the stake beyond 9.99% without further corporate action or changes in outstanding share count.

Future Outlook

The filing does not contain forward-looking statements or guidance from ProMIS Neurosciences. It solely reports on the beneficial ownership of securities by Wellington Management Group LLP and its affiliates.

Industry Context

StockSavvy.ai notes that a Schedule 13G filing from a prominent investment manager like Wellington Management often signifies a passive investment approach, but the details regarding warrant holdings and exercise limitations warrant close monitoring for any potential shifts in strategy or influence.

Comparison to Industry Standards

• Wellington Management Group LLP is a global investment management firm managing assets for institutional and individual clients. Their investment decisions are typically based on extensive research and analysis.
• A 10% stake in a company of ProMIS Neurosciences' size is a significant holding for an institutional investor, especially when filed on a Schedule 13G, which is generally for passive investors.
• The inclusion of warrants in the beneficial ownership calculation is a common practice, but the 9.99% issuance limitation is a specific detail that differentiates this holding from a straightforward equity position.

Stakeholder Impact

• Shareholders: Increased institutional ownership may lead to greater market liquidity and potentially more analyst coverage. The passive nature of the filing suggests no immediate intent to influence control, but future actions could impact share price.
• Creditors: No direct impact indicated by this filing.
• Employees: No direct impact indicated by this filing.
• Customers/Suppliers: No direct impact indicated by this filing.

Next Steps

• Monitor future filings from Wellington Management Group LLP for any changes in beneficial ownership.
• Observe ProMIS Neurosciences' operational and financial performance to assess the underlying value of the company.

Key Dates

Keywords

ProMIS Neurosciences, Wellington Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Warrants, SEC Filing